Basilea Pharmaceutica AG
BPMUF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $103,960 | $132,250 | $76,293 | $72,729 |
| % Growth | -21.4% | 73.3% | 4.9% | – |
| Cost of Goods Sold | $62,524 | -$13,035 | $51,716 | $16,798 |
| Gross Profit | $41,436 | $145,285 | $24,577 | $55,931 |
| % Margin | 39.9% | 109.9% | 32.2% | 76.9% |
| R&D Expenses | $38,294 | $43,545 | $33,598 | $56,385 |
| G&A Expenses | $0 | $31,542 | $0 | $0 |
| SG&A Expenses | $17,053 | $16,481 | $15,061 | $17,239 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$37,943 | $33,338 | -$33,338 | $0 |
| Operating Expenses | $17,404 | $93,364 | $15,321 | $73,624 |
| Operating Income | $24,032 | $51,921 | $9,256 | -$17,693 |
| % Margin | 23.1% | 39.3% | 12.1% | -24.3% |
| Other Income/Exp. Net | -$4,687 | $1,014 | -$1,931 | -$3,713 |
| Pre-Tax Income | $19,345 | $52,935 | $7,325 | -$21,406 |
| Tax Expense | $3,543 | -$3,921 | -$13,412 | -$17 |
| Net Income | $15,802 | $56,856 | $20,737 | -$21,389 |
| % Margin | 15.2% | 43% | 27.2% | -29.4% |
| EPS | 1.29 | 4.7 | 1.61 | -1.78 |
| % Growth | -72.6% | 191.9% | 190.4% | – |
| EPS Diluted | 1.26 | 4.2 | 1.5 | -1.78 |
| Weighted Avg Shares Out | 12,505 | 12,090 | 12,853 | 12,002 |
| Weighted Avg Shares Out Dil | 13,848 | 13,855 | 13,822 | 12,002 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $162 | $1,254 | $1,200 |
| Interest Expense | $1,369 | -$3,284 | $7,628 | $9,760 |
| Depreciation & Amortization | $716 | $1,094 | $639 | $624 |
| EBITDA | $25,099 | $56,182 | $10,155 | $3,146 |
| % Margin | 24.1% | 42.5% | 13.3% | 4.3% |